<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00600015</url>
  </required_header>
  <id_info>
    <org_study_id>SCRI LUN 160</org_study_id>
    <nct_id>NCT00600015</nct_id>
  </id_info>
  <brief_title>Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Randomized Double-Blind Placebo-Controlled Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SCRI Development Innovations, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SCRI Development Innovations, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will investigate the use of the newer targeted agents erlotinib and sorafenib in
      patients with stage IIIB or stage IV NSCLC who have received 1-2 prior chemotherapy regimens.
      Patients will be randomized to receive erlotinib (150 mg/day) and sorafenib (400 mg twice
      daily), or erlotinib (150 mg/day) and a placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The rationale of this study is to combine two distinct kinase inhibitors to evaluate
      synergistic inhibition of angiogenesis and epidermal growth factor receptor (EGFR) signaling.
      Erlotinib is a oral tyrosine kinase inhibitor that targets EGFR. Sorafenib is a oral tyrosine
      kinase inhibitor targeting vascular endothelial growth factor receptor (VEGFR), platelet
      derived growth factor receptor beta, Raf-1, Flt-3, and C-kit. These agents also do not
      exhibit overlapping adverse event profiles which provided additional support for studying
      this combination therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Objective Response Rate (ORR)</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month PFS</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">166</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib + Sorafenib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Erlotinib + Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib + Sorafenib</intervention_name>
    <description>Patients who are randomized to Cohort A will take sorafenib 400 mg (2 x 200-mg tablets) orally twice a day, and erlotinib 150 mg orally once a day.</description>
    <arm_group_label>Combination Therapy</arm_group_label>
    <other_name>Tarceva</other_name>
    <other_name>Nexavar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib + Placebo</intervention_name>
    <description>Patients who are randomized to Cohort B will take erlotinib 150 mg orally once a day and placebo orally twice a day.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed locally advanced or metastatic NSCLC (unresectable stage IIIB
             or stage IV). Eligible histologies include adenocarcinoma and squamous cell carcinoma.
             Patients with recurrent disease after treatment for localized NSCLC are also eligible.
             Cytologic specimens obtained by brushings, washings, or needle aspiration are
             acceptable.

          -  At least one lesion that can be accurately measured in at least one dimension (longest
             diameter to be recorded) as &gt;= 20 mm with conventional techniques, or as &gt;= 10 mm with
             spiral computerized tomography (CT) scan according to the Response Evaluation Criteria
             in Solid Tumors (RECIST).

          -  Failure of at least one, and no more than two prior cytotoxic chemotherapy regimens
             for advanced disease (either due to progressive disease or toxicity).

          -  Recovery from any toxic effects of prior therapy to &lt;= grade 1.

          -  Completion of radiation therapy at least 28 days prior to the start of study treatment
             (not including palliative local radiation). Previously irradiated lesions in the
             advanced setting cannot be included as target lesions unless clear tumor progression
             has been observed since the end of radiation.

          -  An ECOG performance status of 0-2.

          -  Absolute neutrophil count (ANC) &gt;= 1,500, platelets &gt;= 75,000.

          -  Hemoglobin &gt;= 9 g/dL (within 7 days prior to study treatment).

          -  International normalized ratio (INR) &lt;= 1.5 or prothrombin time (PT)/partial
             thromboplastin time (PTT) within normal limits (WNL) of the institution

          -  Serum creatinine &lt;= 1.5 x institutional upper limit of normal (ULN) within 7 days
             prior to study treatment.

          -  Transaminases &lt;= 3 x institutional ULN

          -  Agreement of female patients of childbearing potential and male patients who have
             partners of childbearing potential to use an effective form of contraception to
             prevent pregnancy during treatment, and for a minimum of 90 days thereafter.

          -  Patients who have treated brain metastases &gt;= 4 weeks out (with surgery and/or
             radiation therapy) and no evidence of CNS progression.

        Exclusion Criteria:

          -  Past or current history of neoplasm (other than the entry diagnosis), with the
             exception of treated non-melanoma skin cancer or carcinoma in-situ of the cervix, or
             other cancers cured by local therapy alone, and a disease-free survival (DFS) &gt;= 3
             years.

          -  Patients who have mixed tumors with small-cell elements are ineligible.

          -  Pregnancy or lactation.

          -  Prior treatment with EGFR TKIs or VEGFR TKIs for NSCLC. [NOTE: prior cetuximab and/or
             bevacizumab use is permitted].

          -  Significant cardiac disease within 90 days of starting study treatment

          -  Myocardial infarction within 6 months prior to initiation of study treatment.

          -  Cardiomegaly on chest imaging or ventricular hypertrophy on electrocardiogram (ECG)

          -  Poorly controlled hypertension

          -  Unstable angina (anginal symptoms at rest).

          -  Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.

          -  Presence of cardiac disease that, in the opinion of the investigator, increases the
             risk of ventricular arrhythmia.

          -  A serious underlying medical condition that would impair the ability of the patient to
             receive protocol treatment.

          -  A major surgical procedure, open biopsy, or significant traumatic injury within 28
             days of beginning treatment, or anticipation of the need for major surgery during the
             course of the study.

          -  Stroke or transient ischemic attack (TIA) within the past 6 months.

          -  Any prior history of hypertensive crisis or hypertensive encephalopathy.

          -  Pulmonary hemorrhage/bleeding event &gt;= grade 2 within 28 days of study treatment.

          -  Any other non-pulmonary hemorrhage/bleeding event &gt;= grade 3 within 28 days of study
             treatment.

          -  Evidence or history of bleeding diathesis or coagulopathy.

          -  Serious non-healing wound, ulcer, or bone fracture.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Spigel, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>SCRI Development Innovations, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Georgia Medical Center</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellstar Cancer Research</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Cancer Centers</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Rapids Clinical Oncology Program</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Cancer Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care of Western North Carolina</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Ohio Oncology/Hematology, Inc./ The Mark H. Zangmeister Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Carolina Oncology Associates, PA</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga Oncology Hematology Associates</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Cancer Center</name>
      <address>
        <city>Collierville</city>
        <state>Tennessee</state>
        <zip>38017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Bend Cancer Center</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78463</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Institute</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Spigel DR, Burris HA 3rd, Greco FA, Shipley DL, Friedman EK, Waterhouse DM, Whorf RC, Mitchell RB, Daniel DB, Zangmeister J, Bass JD, Hainsworth JD. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2011 Jun 20;29(18):2582-9. doi: 10.1200/JCO.2010.30.7678. Epub 2011 May 16.</citation>
    <PMID>21576636</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>January 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2008</study_first_posted>
  <results_first_submitted>August 22, 2012</results_first_submitted>
  <results_first_submitted_qc>August 22, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 21, 2012</results_first_posted>
  <last_update_submitted>August 22, 2012</last_update_submitted>
  <last_update_submitted_qc>August 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>Advanced</keyword>
  <keyword>Sorafenib</keyword>
  <keyword>Erlotinib</keyword>
  <keyword>Double-blind</keyword>
  <keyword>Placebo-controlled</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Combination Therapy</title>
          <description>Erlotinib + Sorafenib</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Erlotinib + Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51">Completed &gt;=2 cycles</participants>
                <participants group_id="P2" count="20">Completed &gt;=2 cycles</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Combination Therapy</title>
          <description>Erlotinib + Sorafenib</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Erlotinib + Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="111"/>
            <count group_id="B2" value="55"/>
            <count group_id="B3" value="166"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" lower_limit="44" upper_limit="88"/>
                    <measurement group_id="B2" value="65" lower_limit="45" upper_limit="83"/>
                    <measurement group_id="B3" value="65" lower_limit="44" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Objective Response Rate (ORR)</title>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>Erlotinib + Sorafenib</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Erlotinib + Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Objective Response Rate (ORR)</title>
          <units>Percent</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" lower_limit="3.77" upper_limit="14.83"/>
                    <measurement group_id="O2" value="10.9" lower_limit="4.11" upper_limit="22.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS)</title>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>Erlotinib + Sorafenib</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.38" lower_limit="2.30" upper_limit="3.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate (DCR)</title>
        <time_frame>18 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <time_frame>18 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>6-month PFS</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>Erlotinib + Sorafenib</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Erlotinib + Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.62" lower_limit="5.35" upper_limit="10.54"/>
                    <measurement group_id="O2" value="7.23" lower_limit="4.04" upper_limit="12.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Study Participants</title>
          <description>Reported SAEs and AEs for all study participants -
Combination Therapy: Erlotinib + Sorafenib Placebo: Erlotinib + Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiopulmonary Arrest</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Supraventricular Arrhythmia - Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Supraventricular Arrhythmia - Atrial Tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Supraventricular Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Cardiac Troponin I</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Obstruction - Small Bowel</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Fistula - Esophagus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Perforation - Small Bowel</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <description>Diverticulitis</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <description>GERD</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Obstruction - Esophagus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver Dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Fungal Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Failure To Thrive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Musculoskeletal - Other</sub_title>
                <description>Diskitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Progressive Disease</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Neurology - Other</sub_title>
                <description>Neurodeficit</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Mental Status</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>CNS Ischemia</sub_title>
                <description>CVA</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <description>Hematuria</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>ARDS</sub_title>
                <description>Adult Respiratory Distress Syndrome</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Airway Obstruction - COPD</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/Thrombis/Embolism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="141" subjects_affected="141" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="121" subjects_affected="121" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="84" subjects_affected="84" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="120" subjects_affected="120" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="109" subjects_affected="109" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Hand-Foot</sub_title>
                <counts group_id="E1" events="43" subjects_affected="43" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can review/embargo results communications prior to public release for a period that is &gt;60 days but â‰¤180 days from date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish its results until 18 mos. after the trial has been completed at all sites.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John D. Hainsworth, MD</name_or_title>
      <organization>Sarah Cannon Research Institute</organization>
      <phone>877-691-7274</phone>
      <email>ASKSARAH@scresearch.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

